0001123292-18-000997.txt : 20181003 0001123292-18-000997.hdr.sgml : 20181003 20181003184218 ACCESSION NUMBER: 0001123292-18-000997 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181001 FILED AS OF DATE: 20181003 DATE AS OF CHANGE: 20181003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shaw Allan CENTRAL INDEX KEY: 0001626850 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33389 FILM NUMBER: 181106493 MAIL ADDRESS: STREET 1: C/O CELSUS THERAPEUTICS PLC STREET 2: 24 WEST 40TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VIVUS INC CENTRAL INDEX KEY: 0000881524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943136179 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 900 E. HAMILTON AVENUE STREET 2: SUITE 550 CITY: CAMPBELL STATE: CA ZIP: 95008 BUSINESS PHONE: 6509345200 MAIL ADDRESS: STREET 1: 900 E. HAMILTON AVENUE STREET 2: SUITE 550 CITY: CAMPBELL STATE: CA ZIP: 95008 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-10-01 0000881524 VIVUS INC VVUS 0001626850 Shaw Allan C/O VIVUS, INC. 900 E. HAMILTON AVE., SUITE 550 CAMPBELL CA 95008 1 0 0 0 Common Stock 2018-10-01 4 M 0 139 A 6432 D Common Stock 2018-10-01 4 F 0 43 5.63 D 6389 D On September 10, 2018, VIVUS, Inc. effected a 1-for-10 reverse stock split (the "Reverse Split"). Accordingly, 1,389 shares of common stock on a pre-Reverse Split basis were adjusted to 139 shares following the Reverse Split (with fractional shares rounded up to the next whole number). The shares of common stock relate to the previously disclosed restricted stock units that vested on September 15, 2018 and released on October 1, 2018. Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting. The number of shares beneficially owned following the reported transaction has been adjusted to reflect the Reverse Split (with fractional shares rounded up to the next whole number). The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability. The price reported for the securities is the market value on the business day immediately before September 15, 2018. /s/ Julie Hollenback, Attorney-in-Fact 2018-10-03